Teriparatide

Red

Brand Name(s):Forsteo Movymia(biosimilar)

Indication:Osteoporosis

Rationale:1,8

Considered:Oct-06

Review Date:Sep-21

Comments:
Teriparatide is recommended as an alternative treatment option for the secondary prevention of osteoporotic fragility fractures in postmenopausal women:
* who are unable to take alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate (as defined in section 1.6), or who have a contraindication to, or are intolerant of strontium ranelate (as defined in section 1.7), or who have had an unsatisfactory response (as defined in section 1.8) to treatment with alendronate, risedronate or etidronate and
* who are 65 years or older and have a T-score of minus 4.0 SD or below, or a T-score of minus 3.5 SD or below plus more than two fractures, or who are aged 55 to64 years and have a T-score of minus 4 SD or below plus more than two fractures.

NICE TA 161
Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women OCT 2008